These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 38116854)
21. Cereblon neo-substrate binding mimics the recognition of the cyclic imide degron. Heim C; Spring AK; Kirchgäßner S; Schwarzer D; Hartmann MD Biochem Biophys Res Commun; 2023 Feb; 646():30-35. PubMed ID: 36701892 [TBL] [Abstract][Full Text] [Related]
22. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs. Ito T; Handa H Int J Hematol; 2016 Sep; 104(3):293-9. PubMed ID: 27460676 [TBL] [Abstract][Full Text] [Related]
23. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs. Gemechu Y; Millrine D; Hashimoto S; Prakash J; Sanchenkova K; Metwally H; Gyanu P; Kang S; Kishimoto T Proc Natl Acad Sci U S A; 2018 Nov; 115(46):11802-11807. PubMed ID: 30373817 [TBL] [Abstract][Full Text] [Related]
24. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase. Petzold G; Fischer ES; Thomä NH Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574 [TBL] [Abstract][Full Text] [Related]
26. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201 [TBL] [Abstract][Full Text] [Related]
27. Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands. Xu H; Kurohara T; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y Bioorg Med Chem; 2023 May; 86():117293. PubMed ID: 37126968 [TBL] [Abstract][Full Text] [Related]
29. Differential Analysis of Cereblon Neosubstrates in Rabbit Embryos Using Targeted Proteomics. Federspiel JD; Catlin NR; Nowland WS; Stethem CM; Mathialagan N; Fernandez Ocaña M; Bowman CJ Mol Cell Proteomics; 2024 Jul; 23(7):100797. PubMed ID: 38866076 [TBL] [Abstract][Full Text] [Related]
30. Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation. Liu H; Ding X; Liu L; Mi Q; Zhao Q; Shao Y; Ren C; Chen J; Kong Y; Qiu X; Elvassore N; Yang X; Yin Q; Jiang B Eur J Med Chem; 2021 Nov; 223():113645. PubMed ID: 34217059 [TBL] [Abstract][Full Text] [Related]
31. Cereblon modulators: Low molecular weight inducers of protein degradation. Chamberlain PP; Cathers BE Drug Discov Today Technol; 2019 Apr; 31():29-34. PubMed ID: 31200856 [TBL] [Abstract][Full Text] [Related]
32. Redirecting the Neo-Substrate Specificity of Cereblon-Targeting PROTACs to Helios. Verano AL; You I; Donovan KA; Mageed N; Yue H; Nowak RP; Fischer ES; Wang ES; Gray NS ACS Chem Biol; 2022 Sep; 17(9):2404-2410. PubMed ID: 36007246 [TBL] [Abstract][Full Text] [Related]
33. The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling. Shen C; Nayak A; Neitzel LR; Adams AA; Silver-Isenstadt M; Sawyer LM; Benchabane H; Wang H; Bunnag N; Li B; Wynn DT; Yang F; Garcia-Contreras M; Williams CH; Dakshanamurthy S; Hong CC; Ayad NG; Capobianco AJ; Ahmed Y; Lee E; Robbins DJ Nat Commun; 2021 Sep; 12(1):5263. PubMed ID: 34489457 [TBL] [Abstract][Full Text] [Related]
34. Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy. Costacurta M; He J; Thompson PE; Shortt J J Pers Med; 2021 Nov; 11(11):. PubMed ID: 34834536 [TBL] [Abstract][Full Text] [Related]
35. Synthesis and Evaluation of Cereblon-Recruiting HaloPROTACs. Ody BK; Zhang J; Nelson SE; Xie Y; Liu R; Dodd CJ; Jacobs SE; Whitzel SL; Williams LA; Gozem S; Turlington M; Yin J Chembiochem; 2023 Nov; 24(21):e202300498. PubMed ID: 37625128 [TBL] [Abstract][Full Text] [Related]
36. Synthesis of novel glutarimide ligands for the E3 ligase substrate receptor Cereblon (CRBN): Investigation of their binding mode and antiproliferative effects against myeloma cell lines. Krasavin M; Adamchik M; Bubyrev A; Heim C; Maiwald S; Zhukovsky D; Zhmurov P; Bunev A; Hartmann MD Eur J Med Chem; 2023 Jan; 246():114990. PubMed ID: 36476642 [TBL] [Abstract][Full Text] [Related]
37. Protein degraders - from thalidomide to new PROTACs. Ito T J Biochem; 2024 Apr; 175(5):507-519. PubMed ID: 38140952 [TBL] [Abstract][Full Text] [Related]
38. Cereblon: promise and challenges for combating human diseases. Kim HK; Seol JE; Ahn SW; Jeon S; Park CS; Han J Pflugers Arch; 2021 Nov; 473(11):1695-1711. PubMed ID: 34553266 [TBL] [Abstract][Full Text] [Related]
39. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera. Kim K; Lee DH; Park S; Jo SH; Ku B; Park SG; Park BC; Jeon YU; Ahn S; Kang CH; Hwang D; Chae S; Ha JD; Kim S; Hwang JY; Kim JH Sci Rep; 2019 Dec; 9(1):19654. PubMed ID: 31873151 [TBL] [Abstract][Full Text] [Related]
40. A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. Wurz RP; Dellamaggiore K; Dou H; Javier N; Lo MC; McCarter JD; Mohl D; Sastri C; Lipford JR; Cee VJ J Med Chem; 2018 Jan; 61(2):453-461. PubMed ID: 28378579 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]